

February 2023 Shareholder Update

Dear Neopharma Technologies Shareholders

I am pleased to provide the following updates:

- 1) Neopharma Technologies has passed the preliminary evaluation for our Saliva Drug Test by Australian laboratory, Racing Analytical Services Ltd for Australian Market Entry.
- 2) We have lodged all US FDA documentation for our NEOTEST Drug Test range, and we are expected to receive an approval within 4 – 6 weeks.
- 3) Neopharma Technologies has purchased and secured the NEOTEST.com domain and secured US Toll-Free Number 1844 NEOTEST; we have received confirmation from USPTO that our Trademark NEOTEST will receive NEOTEST® (registered mark) once we send them a snapshot of us selling our products on any e-commerce site including ours. This will be timed in alignment with US FDA approval.
- 4) TamperLoks is going through clinical evaluation and producing 7,000 units for assembly. Our team is working closely with WHPM Inc in setting up the production line. With the balance of funds from the PRE IPO raise, \$250,000 will be allocated to invest in a dedicated hard mould to support production for the US market entry for TamperLoks.
- 5) Neopharma Technologies has signed an MOU for the Saudi Arabia and UAE markets for our NEOTEST range; there is strong interest in bringing our products, including TamperLoks, to this market. The key terms of the MOU are; to maintain exclusivity, minimum order commitments of 50,000 units in Year 1, 100,000 units in Year 2, and 150,000 units in year 3. However, there is an expectation to do a multiple of this number given the market growth opportunities in the middle east.
- 6) Our NEOTEST Drug Test range was submitted to MDA for the Malaysian market. Due to the lower cost of production, this range of products, including our Dip Card, can meet the market price for Malaysia with very healthy profit margins for Neopharma Technologies.
- 7) NEOVAULT's AI for vision, which enables test strip image recognition and labelling will be enabled for the US market entry. This AI software gives us our clear market advantage paired with our now extensive range of Drug Testing products.
- 8) Neopharma's official US market launch is scheduled for May, aligning with our US FDA approvals and ISO27001, HIPAA and SOC2 accreditations for NEOVAULT. This enables us to hit the market aggressively with a full suite of products with healthy margins, with our clear advantage of AI technology and our NEOVAULT Enterprise Resource Platform for managing workplace testing.

We have raised \$1,114,843 of the \$2,000,000 PRE IPO capital raise. The investment opportunity remains open for 30 cent shares + 1 free attaching option at with a 30 cent strike price and a 2 year expiry.

We have secured the code ASX: NEO, and our planned IPO is to raise \$8,000,000 at 50 cents/share off the back of US Market entry. We are positioning our company as a rare ASX-listed company that would have received US FDA approval for a range of IVDs.



NEOPHARMA TECHNOLOGIES

DO YOU NEED FAST AND ACCURATE DRUG TEST RESULTS?

Welcome to the worlds leading Drugs of Abuse test kits enhanced by **NEOVAULT**

NEOTEST Drug Test Cup

NEOTEST Drug Test

NEOTEST Drug Test Oral Fluid Cup

CALL NOW TOLL FREE 1844 NEOTEST

enquiries@neopharmatechnologies.com | www.neopharmatechnologies.com